Fiscal Year Earnings Estimate on Actinium Pharmaceuticals, Inc.(ATNM)

Actinium Pharmaceuticals, Inc.(ATNM):Based on the filings, last years Annual Earnings was, $-0.55. The consensus estimate for current quarter is $-0.23 and for the current fiscal year, the estimate is $-0.65. For the Next fiscal year, the estimate is $-0.58 based on the consensus.

Actinium Pharmaceuticals, Inc. has received $-0.23 as the consensus Earnings Estimate for the Quarter ending on Dec 2016 ,According to the estimate provided by 2 Financial Advisor in the Stock Trading Firms. Among 2 Analysts, Bottom line EPS Estimate for the current quarter is $-0.31 while the top line estimate is $-0.14 , a key information to consider for Day Trading and investing in stocks. The EPS growth rate is projected at -40.63%. Actinium Pharmaceuticals, Inc. reported better than expected with a surprise EPS of % or $ during its most recent quarterly earnings. The Actual EPS was $ compared to the Estimated EPS of $.

Company has reported several Insider transactions to the SEC, on Jan 3, 2017, Sandesh Seth (Executive Chairman) purchased 5,000 shares at 0.88 per share price.On Sep 1, 2016, Sloan-kettering Cance Memorial (10% owner) sold 192,927 shares at 1.82 per share price.On Apr 18, 2016, C. David Nicholson, (director) purchased 5,000 shares at 2.00 per share price.

Actinium Pharmaceuticals, Inc. (NYSEMKT:ATNM) rose 1.32% or 0.02 points on Wednesday and made its way into the gainers of the day. After trading began at $1.54 the stock was seen hitting $1.63 as a peak level and $1.5 as the lowest level. The stock ended up at $1.54. The daily volume was measured at 1,119,644 shares. The 52-week high of the share price is $2.3599 and the 52-week low is $0.86. The company has a market cap of $86 million.

Actinium Pharmaceuticals, Inc. is a biopharmaceutical company. It specializes in the development of cancer drugs. The companys principal product candidates under different developmental stages include Actimab-A for the treatment of acute myeloid leukemia in elderly patients and Iomab-B used to condition the bone marrow of patients. Actinium Pharmaceuticals, Inc. is based in New York.


Add Comment